-
公开(公告)号：US09889206B2
公开(公告)日：2018-02-13
申请号：US14485062
申请日：2014-09-12
Applicant: Samsung Electronics Co., Ltd.
Inventor： Su Young Chae , Sunghyun Kim , Eun Ko , Yun Ju Jeong , Jae Hyun Choi
IPC: A61K39/395 , A61K47/48
CPC classification number: A61K47/6859 , A61K47/6803 , A61K47/6851
Abstract: Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof.
-
公开(公告)号：US20150140014A1
公开(公告)日：2015-05-21
申请号：US14081886
申请日：2013-11-15
Applicant: Samsung Electronics Co., Ltd.
Inventor： Seung Hyun LEE , Geun Woong Kim , Kyung Ah Kim , Hye Won Park , Ho Yeong Song , Young Mi Oh , Saet Byoul Lee , Ji Min Lee , Kwang Ho Cheong , Yun Ju Jeong , Mi Young Cho , Jae Hyun Choi , Yun Jeong Song , Yoon Aa Choi
IPC: C07K14/71 , A61K31/437 , A61K31/44 , A61K39/395 , A61K31/517
CPC classification number: A61K31/437 , A61K31/44 , A61K31/517 , A61K39/3955 , A61K39/39558 , C07K16/2863 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/30 , C12N5/163 , A61K2300/00
Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
Abstract translation: 一种预防或治疗癌症的方法，包括共同给予（a）抗c-Met抗体或其抗原结合片段，和（b）拉帕替尼，替罗非尼，伏马拉净或其组合中的至少一种， （a）抗c-Met抗体或其抗原结合片段，和（b）拉帕替尼，替罗非尼，伏马拉净或其组合中的至少一种提供给药物组合物 。
-
公开(公告)号：US09869668B2
公开(公告)日：2018-01-16
申请号：US14836596
申请日：2015-08-26
Inventor： Jae Hyun Choi , Kyung Ah Kim , Youngwook Kim , Keunchil Park
IPC: G01N33/50
CPC classification number: G01N33/5011 , G01N2333/49 , G01N2800/52
Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.
-
4.发明申请公开(公告)号：US20150071950A1
公开(公告)日：2015-03-12
申请号：US14485062
申请日：2014-09-12
Applicant: Samsung Electronics Co., Ltd.
Inventor： Su Young Chae , Sunghyun Kim , Eun Ko , Yun Ju Jeong , Jae Hyun Choi
IPC: A61K47/48 , A61K31/337
CPC classification number: A61K47/6859 , A61K47/6803 , A61K47/6851
Abstract: Disclosed is a conjugate in which a c-Met targeting compound and a bioactive material are chemically conjugated with each other, and methods of use thereof.
Abstract translation: 公开了一种其中c-Met靶向化合物和生物活性物质彼此化学共轭的缀合物及其使用方法。
-
5.发明申请METHOD OF COMBINATION THERAPY USING AN EGFR ANTAGONIST AND ANTI-C-MET ANTIBODY 有权使用EGFR拮抗剂和抗C-MET抗体的组合治疗方法公开(公告)号：US20140294830A1
公开(公告)日：2014-10-02
申请号：US14227759
申请日：2014-03-27
Inventor： Saet Byoul LEE , Jae Hyun Choi , Kyung Ah Kim , Ji Min Lee , Yun Ju Jeong
IPC: A61K39/395 , A61K31/5377 , A61K31/517
CPC classification number: A61K39/3955 , A61K31/517 , A61K31/5377 , A61K31/00 , A61K2300/00
Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.
Abstract translation: 用于预防和/或治疗c-Met-和/或EGFR诱导的疾病的组合疗法的方法，包括将药学有效量的EGFR拮抗剂和药学上有效量的抗c-Met抗体共同施用于 提供了有需要的受试者。
-
Patent Agency Ranking
公开(公告)号：US10792371B2
公开(公告)日：2020-10-06
申请号：US15884963
申请日：2018-01-31
Applicant: Samsung Electronics Co., Ltd.
Inventor： Su Young Chae , Sunghyun Kim , Eun Ko , Yun Ju Jeong , Jae Hyun Choi
Abstract: Provided is a conjugate including a c-Met targeting compound and a bioactive material and methods of use of the conjugate.
-
7.发明授权Method of combination therapy using an EGFR antagonist and anti-c-Met antibody 有权使用EGFR拮抗剂和抗c-Met抗体的联合治疗方法公开(公告)号：US09572878B2
公开(公告)日：2017-02-21
申请号：US14227759
申请日：2014-03-27
Inventor： Saet Byoul Lee , Jae Hyun Choi , Kyung Ah Kim , Ji Min Lee , Yun Ju Jeong , Keunchil Park , Youngwook Kim , Yumi Lee
IPC: A61K39/395 , A61K31/517 , A61K31/5377
CPC classification number: A61K39/3955 , A61K31/517 , A61K31/5377 , A61K31/00 , A61K2300/00
Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.
Abstract translation: 用于预防和/或治疗c-Met-和/或EGFR诱导的疾病的组合疗法的方法，包括将药学有效量的EGFR拮抗剂和药学上有效量的抗c-Met抗体共同施用于 提供了有需要的受试者。
-
8.发明申请PDGF AS A BIOMARKER FOR PREDICTING RESISTANCE OR EFFECT OF C-MET TARGETING DRUGS 有权PDGF作为预测C-MET靶向药物的电阻或效应的生物标志物公开(公告)号：US20160061815A1
公开(公告)日：2016-03-03
申请号：US14836596
申请日：2015-08-26
Inventor： Jae Hyun Choi , Kyung Ah Kim , Youngwook Kim , Keunchil Park
IPC: G01N33/50
CPC classification number: G01N33/5011 , G01N2333/49 , G01N2800/52
Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.
Abstract translation: 提供了评估c-Met靶向剂的功效或抗性的方法，包括测量PDGF蛋白和/或PDGF编码基因的水平。
-
公开(公告)号：US20180236097A1
公开(公告)日：2018-08-23
申请号：US15884963
申请日：2018-01-31
Applicant: Samsung Electronics Co., Ltd.
Inventor： Su Young Chae , Sunghyun Kim , Eun Ko , Yun Ju Jeong , Jae Hyun Choi
IPC: A61K47/68
Abstract: Provided is a conjugate including a c-Met targeting compound and a bioactive material and methods of use of the conjugate.
-
10.发明授权公开(公告)号：US09931400B2
公开(公告)日：2018-04-03
申请号：US14025403
申请日：2013-09-12
Applicant: Samsung Electronics Co., Ltd.
Inventor： Yun Ju Jeong , Kyung Ah Kim , Yun Jeong Song , Ji Min Lee , Hyo Seon Lee , Jae Hyun Choi , Saet Byoul Lee
IPC: A61K39/395 , A61K45/06 , C07K16/28
CPC classification number: A61K39/3955 , A61K45/06 , C07K16/2863 , C07K2317/24
Abstract: Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.016 seconds)
